Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)

Authors :: L. Salvatore
F. Ciardiello
S. Cascinu
A. Sobrero
C. Banzi
C. Barone
F. Gelsomino
E. Maiello
S. Siena
F. Bergamo
G. Cartenì
F. Di Costanzo
M. Di Bartolomeo
L. Rimassa
A. Russo
M. Moscovici
E. Van Cutsem
A. Grothey
A. Zaniboni
Source :: Annals of Oncology. 27:iv47
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Full Text Access

Tools